10:08 AM EST, 11/24/2025 (MT Newswires) -- Jyong Biotech ( MENS ) said Monday that it signed a non-binding letter of intent with a South Korean pharmaceutical company to assess the potential in-licensing and development of Jyong Biotech's ( MENS ) MCS-2 candidate in South Korea.

The company said definitive terms are still being negotiated and the LOI remains subject to due diligence, regulatory review, and other conditions.

MCS-2 is not yet approved for commercial use in any market, Jyong Biotech ( MENS ) said.

Shares of Jyong Biotech ( MENS ) were up more than 5% in recent Monday trading.

Price: 32.03, Change: +1.29, Percent Change: +4.18